{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:43:59Z","timestamp":1790844239131,"version":"4.1.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2015,4,28]],"date-time":"2015-04-28T00:00:00Z","timestamp":1430179200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,4,28]],"date-time":"2015-04-28T00:00:00Z","timestamp":1430179200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1038\/leu.2015.105","type":"journal-article","created":{"date-parts":[[2015,4,28]],"date-time":"2015-04-28T06:43:00Z","timestamp":1430203380000},"page":"1811-1822","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":152,"title":["The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K\/AKT\/S6 pathway and promotes apoptosis in CLL"],"prefix":"10.1038","volume":"29","author":[{"given":"K","family":"Balakrishnan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Peluso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N Y","family":"Rosin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J A","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W G","family":"Wierda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M J","family":"Keating","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Faia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J L","family":"Kutok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,4,28]]},"reference":[{"key":"BFleu2015105_CR1","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","volume":"376","author":"M Hallek","year":"2010","unstructured":"Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010; 376: 1164\u20131174.","journal-title":"Lancet"},{"key":"BFleu2015105_CR2","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa1315226","volume":"370","author":"RR Furman","year":"2014","unstructured":"Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014; 370: 997\u20131007.","journal-title":"N Engl J Med"},{"key":"BFleu2015105_CR3","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1215637","volume":"369","author":"JC Byrd","year":"2013","unstructured":"Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013; 369: 32\u201342.","journal-title":"N Engl J Med"},{"key":"BFleu2015105_CR4","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1146\/annurev.immunol.22.012703.104721","volume":"22","author":"JA Deane","year":"2004","unstructured":"Deane JA, Fruman DA . Phosphoinositide 3-kinase: diverse roles in immune cell activation. Annu Rev Immunol 2004; 22: 563\u2013598.","journal-title":"Annu Rev Immunol"},{"key":"BFleu2015105_CR5","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/nrd4204","volume":"13","author":"DA Fruman","year":"2014","unstructured":"Fruman DA, Rommel C . PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov 2014; 13: 140\u2013156.","journal-title":"Nat Rev Drug Discov"},{"key":"BFleu2015105_CR6","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/1741-7015-10-161","volume":"10","author":"I Brana","year":"2012","unstructured":"Brana I, Siu LL . Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment. BMC Med 2012; 10: 161.","journal-title":"BMC Med"},{"key":"BFleu2015105_CR7","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.4049\/jimmunol.173.4.2236","volume":"173","author":"K Reif","year":"2004","unstructured":"Reif K, Okkenhaug K, Sasaki T, Penninger JM, Vanhaesebroeck B, Cyster JG . Cutting edge: differential roles for phosphoinositide 3-kinases, p110gamma and p110delta, in lymphocyte chemotaxis and homing. J Immunol 2004; 173: 2236\u20132240.","journal-title":"J Immunol"},{"key":"BFleu2015105_CR8","doi-asserted-by":"publisher","first-page":"5673","DOI":"10.4049\/jimmunol.0900432","volume":"183","author":"CA Durand","year":"2009","unstructured":"Durand CA, Hartvigsen K, Fogelstrand L, Kim S, Iritani S, Vanhaesebroeck B et al. Phosphoinositide 3-kinase p110 delta regulates natural antibody production, marginal zone and B-1 B cell function, and autoantibody responses. J Immunol 2009; 183: 5673\u20135684.","journal-title":"J Immunol"},{"key":"BFleu2015105_CR9","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1126\/science.1073560","volume":"297","author":"K Okkenhaug","year":"2002","unstructured":"Okkenhaug K, Bilancio A, Farjot G, Priddle H, Sancho S, Peskett E et al. Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science 2002; 297: 1031\u20131034.","journal-title":"Science"},{"key":"BFleu2015105_CR10","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1038\/nature02991","volume":"431","author":"K Ali","year":"2004","unstructured":"Ali K, Bilancio A, Thomas M, Pearce W, Gilfillan AM, Tkaczyk C et al. Essential role for the p110delta phosphoinositide 3-kinase in the allergic response. Nature 2004; 431: 1007\u20131011.","journal-title":"Nature"},{"key":"BFleu2015105_CR11","doi-asserted-by":"publisher","first-page":"5122","DOI":"10.4049\/jimmunol.177.8.5122","volume":"177","author":"K Okkenhaug","year":"2006","unstructured":"Okkenhaug K, Patton DT, Bilancio A, Garcon F, Rowan WC, Vanhaesebroeck B . The p110delta isoform of phosphoinositide 3-kinase controls clonal expansion and differentiation of Th cells. J Immunol 2006; 177: 5122\u20135128.","journal-title":"J Immunol"},{"key":"BFleu2015105_CR12","doi-asserted-by":"publisher","first-page":"6598","DOI":"10.4049\/jimmunol.177.10.6598","volume":"177","author":"DT Patton","year":"2006","unstructured":"Patton DT, Garden OA, Pearce WP, Clough LE, Monk CR, Leung E et al. Cutting edge: the phosphoinositide 3-kinase p110 delta is critical for the function of CD4+CD25+Foxp3+ regulatory T cells. J Immunol 2006; 177: 6598\u20136602.","journal-title":"J Immunol"},{"key":"BFleu2015105_CR13","doi-asserted-by":"crossref","first-page":"691","DOI":"10.14694\/EdBook_AM.2012.32.75","volume":"32","author":"JC Byrd","year":"2012","unstructured":"Byrd JC, Woyach JA, Johnson AJ . Translating PI3K-delta inhibitors to the clinic in chronic lymphocytic leukemia: the story of CAL-101 (GS1101). Am Soc Clin Oncol Educ Book 2012; 32: 691\u2013694.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"BFleu2015105_CR14","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/eji.200838266","volume":"38","author":"TM Randis","year":"2008","unstructured":"Randis TM, Puri KD, Zhou H, Diacovo TG . Role of PI3Kdelta and PI3Kgamma in inflammatory arthritis and tissue localization of neutrophils. Eur J Immunol 2008; 38: 1215\u20131224.","journal-title":"Eur J Immunol"},{"key":"BFleu2015105_CR15","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1182\/blood-2008-02-135715","volume":"112","author":"J Barbi","year":"2008","unstructured":"Barbi J, Cummings HE, Lu B, Oghumu S, Ruckle T, Rommel C et al. PI3Kgamma (PI3Kgamma) is essential for efficient induction of CXCR3 on activated T cells. Blood 2008; 112: 3048\u20133051.","journal-title":"Blood"},{"key":"BFleu2015105_CR16","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1161\/CIRCRESAHA.107.164376","volume":"102","author":"E Chavakis","year":"2008","unstructured":"Chavakis E, Carmona G, Urbich C, Gottig S, Henschler R, Penninger JM et al. Phosphatidylinositol-3-kinase-gamma is integral to homing functions of progenitor cells. Circ Res 2008; 102: 942\u2013949.","journal-title":"Circ Res"},{"key":"BFleu2015105_CR17","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.4049\/jimmunol.180.4.2081","volume":"180","author":"AL Martin","year":"2008","unstructured":"Martin AL, Schwartz MD, Jameson SC, Shimizu Y . Selective regulation of CD8 effector T cell migration by the p110 gamma isoform of phosphatidylinositol 3-kinase. J Immunol 2008; 180: 2081\u20132088.","journal-title":"J Immunol"},{"key":"BFleu2015105_CR18","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1038\/sj.emboj.7600361","volume":"23","author":"A Del Prete","year":"2004","unstructured":"Del Prete A, Vermi W, Dander E, Otero K, Barberis L, Luini W et al. Defective dendritic cell migration and activation of adaptive immunity in PI3Kgamma-deficient mice. EMBO J 2004; 23: 3505\u20133515.","journal-title":"EMBO J"},{"key":"BFleu2015105_CR19","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","volume":"370","author":"AK Gopal","year":"2014","unstructured":"Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 2014; 370: 1008\u20131018.","journal-title":"N Engl J Med"},{"key":"BFleu2015105_CR20","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.1182\/blood-2013-11-535047","volume":"123","author":"JR Brown","year":"2014","unstructured":"Brown JR, Byrd JC, Coutre SE, Benson DM, Flinn IW, Wagner-Johnston ND et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed\/refractory chronic lymphocytic leukemia. Blood 2014; 123: 3390\u20133397.","journal-title":"Blood"},{"key":"BFleu2015105_CR21","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1016\/j.chembiol.2013.09.017","volume":"20","author":"DG Winkler","year":"2013","unstructured":"Winkler DG, Faia KL, DiNitto JP, Ali JA, White KF, Brophy EE et al. PI3K-delta and PI3K-gamma inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem Biol 2013; 20: 1364\u20131374.","journal-title":"Chem Biol"},{"key":"BFleu2015105_CR22","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.chembiol.2013.11.002","volume":"20","author":"K Okkenhaug","year":"2013","unstructured":"Okkenhaug K . Two birds with one stone: dual p110delta and p110gamma inhibition. Chem Biol 2013; 20: 1309\u20131310.","journal-title":"Chem Biol"},{"key":"BFleu2015105_CR23","doi-asserted-by":"crossref","first-page":"3334","DOI":"10.1182\/blood.V124.21.3334.3334","volume":"124","author":"S O'Brien","year":"2014","unstructured":"O'Brien S, Patel M, Kahl BS, Horwitz SM, Foss FM, Porcu P et al. Duvelisib (IPI-145), a PI3K-\u03b4,\u03b3 inhibitor, is clinically active in patients with relapsed\/refractory chronic lymphocytic leukemia. Blood 2014; 124: 3334\u20133334.","journal-title":"Blood"},{"key":"BFleu2015105_CR24","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.1182\/blood-2014-06-576942","volume":"124","author":"P Porcu","year":"2014","unstructured":"Porcu P, Flinn I, Kahl BS, Horwitz SM, Oki Y, Byrd JC et al. Clinical activity of duvelisib (IPI-145), a phosphoinositide-3-kinase-\u03b4,\u03b3 inhibitor, in patients previously treated with ibrutinib. Blood 2014; 124: 3335\u20133335.","journal-title":"Blood"},{"key":"BFleu2015105_CR25","first-page":"802","volume":"124","author":"I Flinn","year":"2014","unstructured":"Flinn I, Oki Y, Patel M, Horwitz SM, Foss FM, Sweeney J et al. A phase 1 evaluation of duvelisib (IPI-145), a PI3K-\u03b4,\u03b3 inhibitor, in patients with relapsed. Refractory iNHL 2014; 124: 802.","journal-title":"Refractory iNHL"},{"key":"BFleu2015105_CR26","first-page":"TPS7122","volume":"32","author":"I Flinn","year":"2014","unstructured":"Flinn I, Jager U, Offner F, Cymbalista F, Hallek M, Caligaris-Cappio F et al. DUO: a phase 3 trial of the PI3K-{delta},{gamma} inhibitor IPI-145 versus ofatumumab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. ASCO Meeting Abstracts 11 June 2014; 32: TPS7122.","journal-title":"ASCO Meeting Abstracts 11 June"},{"key":"BFleu2015105_CR27","first-page":"8518","volume":"31","author":"SM Horwitz","year":"2013","unstructured":"Horwitz SM, Flinn I, Patel MR, Younes A, Foss FM, Oki Y et al. Preliminary safety and efficacy of IPI-145, a potent inhibitor of phosphoinositide-3-kinase-{delta},{gamma}, in patients with relapsed\/refractory lymphoma. ASCO Meeting Abstracts 17 June 2013; 31: 8518.","journal-title":"ASCO Meeting Abstracts 17 June"},{"key":"BFleu2015105_CR28","first-page":"7070","volume":"31","author":"MR Patel","year":"2013","unstructured":"Patel MR, Kahl BS, Horwitz SM, Younes A, Foss FM, Oki Y et al. Preliminary safety and efficacy of IPI-145, a potent inhibitor of phosphoinositide-3-kinase-{delta},{gamma}, in patients with relapsed\/refractory CLL. ASCO Meeting Abstracts 17 June 2013; 31: 7070.","journal-title":"ASCO Meeting Abstracts 17 June"},{"key":"BFleu2015105_CR29","doi-asserted-by":"crossref","first-page":"4167","DOI":"10.1182\/blood.V122.21.4167.4167","volume":"122","author":"K Balakrishnan","year":"2013","unstructured":"Balakrishnan K, Peluso M, Fu M, Rosin NY, Burger JA, Wierda WG et al. Inhibition of PI3K-\u03b4 and -\u03b3 isoforms by IPI-145 in chronic lymphocytic leukemia overcomes signals from PI3K\/AKT\/S6 pathway and promotes apoptosis. Blood 2013; 122: 4167\u20134167.","journal-title":"Blood"},{"key":"BFleu2015105_CR30","doi-asserted-by":"publisher","first-page":"3583","DOI":"10.1182\/blood-2014-07-587279","volume":"124","author":"S Dong","year":"2014","unstructured":"Dong S, Guinn D, Dubovsky JA, Zhong Y, Lehman A, Kutok J et al. IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells. Blood 2014; 124: 3583\u20133586.","journal-title":"Blood"},{"key":"BFleu2015105_CR31","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1182\/blood-2009-10-246199","volume":"116","author":"K Balakrishnan","year":"2010","unstructured":"Balakrishnan K, Burger JA, Quiroga MP, Henneberg M, Ayres ML, Wierda WG et al. Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells. Blood 2010; 116: 1083\u20131091.","journal-title":"Blood"},{"key":"BFleu2015105_CR32","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1182\/blood-2011-10-386417","volume":"119","author":"S Ponader","year":"2012","unstructured":"Ponader S, Chen SS, Buggy JJ, Balakrishnan K, Gandhi V, Wierda WG et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 2012; 119: 1182\u20131189.","journal-title":"Blood"},{"key":"BFleu2015105_CR33","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1182\/blood-2009-03-212837","volume":"114","author":"MP Quiroga","year":"2009","unstructured":"Quiroga MP, Balakrishnan K, Kurtova AV, Sivina M, Keating MJ, Wierda WG et al. B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood 2009; 114: 1029\u20131037.","journal-title":"Blood"},{"key":"BFleu2015105_CR34","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1038\/leu.2009.145","volume":"23","author":"M Plander","year":"2009","unstructured":"Plander M, Seegers S, Ugocsai P, Diermeier-Daucher S, Ivanyi J, Schmitz G et al. Different proliferative and survival capacity of CLL-cells in a newly established in vitro model for pseudofollicles. Leukemia 2009; 23: 2118\u20132128.","journal-title":"Leukemia"},{"key":"BFleu2015105_CR35","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.1182\/blood-2011-05-352492","volume":"118","author":"J Hoellenriegel","year":"2011","unstructured":"Hoellenriegel J, Meadows SA, Sivina M, Wierda WG, Kantarjian H, Keating MJ et al. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 2011; 118: 3603\u20133612.","journal-title":"Blood"},{"key":"BFleu2015105_CR36","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1128\/MCB.01786-07","volume":"28","author":"M Marques","year":"2008","unstructured":"Marques M, Kumar A, Cortes I, Gonzalez-Garcia A, Hernandez C, Moreno-Ortiz MC et al. Phosphoinositide 3-kinases p110alpha and p110beta regulate cell cycle entry, exhibiting distinct activation kinetics in G1 phase. Mol Cell Biol 2008; 28: 2803\u20132814.","journal-title":"Mol Cell Biol"},{"key":"BFleu2015105_CR37","doi-asserted-by":"publisher","first-page":"6537","DOI":"10.2741\/3173","volume":"13","author":"P Nyberg","year":"2008","unstructured":"Nyberg P, Salo T, Kalluri R . Tumor microenvironment and angiogenesis. Front Biosci 2008; 13: 6537\u20136553.","journal-title":"Front Biosci"},{"key":"BFleu2015105_CR38","doi-asserted-by":"publisher","first-page":"7525","DOI":"10.1073\/pnas.0812000106","volume":"106","author":"M Marques","year":"2009","unstructured":"Marques M, Kumar A, Poveda AM, Zuluaga S, Hernandez C, Jackson S et al. Specific function of phosphoinositide 3-kinase beta in the control of DNA replication. Proc Natl Acad Sci USA 2009; 106: 7525\u20137530.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2015105_CR39","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/nrg1879","volume":"7","author":"JA Engelman","year":"2006","unstructured":"Engelman JA, Luo J, Cantley LC . The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006; 7: 606\u2013619.","journal-title":"Nat Rev Genet"},{"key":"BFleu2015105_CR40","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.bbapap.2007.10.003","volume":"1784","author":"R Marone","year":"2008","unstructured":"Marone R, Cmiljanovic V, Giese B, Wymann MP . Targeting phosphoinositide 3-kinase: moving towards therapy. Biochim Biophys Acta 2008; 1784: 159\u2013185.","journal-title":"Biochim Biophys Acta"},{"key":"BFleu2015105_CR41","doi-asserted-by":"publisher","first-page":"245","DOI":"10.2174\/1874312901206010245","volume":"6","author":"E Banham-Hall","year":"2012","unstructured":"Banham-Hall E, Clatworthy MR, Okkenhaug K . The therapeutic potential for PI3K inhibitors in autoimmune rheumatic diseases. Open Rheumatol J 2012; 6: 245\u2013258.","journal-title":"Open Rheumatol J"},{"key":"BFleu2015105_CR42","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1182\/blood-2010-02-271171","volume":"116","author":"SE Herman","year":"2010","unstructured":"Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM et al. Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 2010; 116: 2078\u20132088.","journal-title":"Blood"},{"key":"BFleu2015105_CR43","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1182\/blood-2010-03-275305","volume":"117","author":"BJ Lannutti","year":"2011","unstructured":"Lannutti BJ, Meadows SA, Herman SE, Kashishian A, Steiner B, Johnson AJ et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 2011; 117: 591\u2013594.","journal-title":"Blood"},{"key":"BFleu2015105_CR44","first-page":"7017","volume":"31","author":"JC Barrientos","year":"2013","unstructured":"Barrientos JC, Furman RR, Leonard J, Flinn I, Rai KR, De Vos S et al. Update on a phase I study of the selective PI3K{delta} inhibitor idelalisib (GS-1101) in combination with rituximab and\/or bendamustine in patients with relapsed or refractory CLL. ASCO Meeting Abstracts 2013; 31: 7017.","journal-title":"ASCO Meeting Abstracts"},{"key":"BFleu2015105_CR45","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1182\/blood-2013-11-538546","volume":"123","author":"IW Flinn","year":"2014","unstructured":"Flinn IW, Kahl BS, Leonard JP, Furman RR, Brown JR, Byrd JC et al. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-delta, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood 2014; 123: 3406\u20133413.","journal-title":"Blood"},{"key":"BFleu2015105_CR46","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1146\/annurev-immunol-032712-095946","volume":"31","author":"K Okkenhaug","year":"2013","unstructured":"Okkenhaug K . Signaling by the phosphoinositide 3-kinase family in immune cells. Annu Rev Immunol 2013; 31: 675\u2013704.","journal-title":"Annu Rev Immunol"},{"key":"BFleu2015105_CR47","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.4049\/jimmunol.180.4.2538","volume":"180","author":"K Ali","year":"2008","unstructured":"Ali K, Camps M, Pearce WP, Ji H, Ruckle T, Kuehn N et al. Isoform-specific functions of phosphoinositide 3-kinases: p110 delta but not p110 gamma promotes optimal allergic responses in vivo. J Immunol 2008; 180: 2538\u20132544.","journal-title":"J Immunol"},{"key":"BFleu2015105_CR48","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.ccr.2011.04.016","volume":"19","author":"MC Schmid","year":"2011","unstructured":"Schmid MC, Avraamides CJ, Dippold HC, Franco I, Foubert P, Ellies LG et al. Receptor tyrosine kinases and TLR\/IL1 Rs unexpectedly activate myeloid cell PI3K gamma, a single convergent point promoting tumor inflammation and progression. Cancer Cell 2011; 19: 715\u2013727.","journal-title":"Cancer Cell"},{"key":"BFleu2015105_CR49","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1182\/blood-2010-09-307249","volume":"117","author":"M Sivina","year":"2011","unstructured":"Sivina M, Hartmann E, Kipps TJ, Rassenti L, Krupnik D, Lerner S et al. CCL3 (MIP-1alpha) plasma levels and the risk for disease progression in chronic lymphocytic leukemia. Blood 2011; 117: 1662\u20131669.","journal-title":"Blood"},{"key":"BFleu2015105_CR50","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1084\/jem.177.6.1821","volume":"177","author":"TJ Schall","year":"1993","unstructured":"Schall TJ, Bacon K, Camp RD, Kaspari JW, Goeddel DV . Human macrophage inflammatory protein alpha (MIP-1 alpha) and MIP-1 beta chemokines attract distinct populations of lymphocytes. J Exp Med 1993; 177: 1821\u20131826.","journal-title":"J Exp Med"},{"key":"BFleu2015105_CR51","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1182\/blood-2008-07-170415","volume":"113","author":"JA Burger","year":"2009","unstructured":"Burger JA, Quiroga MP, Hartmann E, Burkle A, Wierda WG, Keating MJ et al. High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. Blood 2009; 113: 3050\u20133058.","journal-title":"Blood"},{"key":"BFleu2015105_CR52","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1182\/blood-2010-05-284984","volume":"117","author":"Y Herishanu","year":"2011","unstructured":"Herishanu Y, Perez-Galan P, Liu D, Biancotto A, Pittaluga S, Vire B et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 2011; 117: 563\u2013574.","journal-title":"Blood"},{"key":"BFleu2015105_CR53","doi-asserted-by":"crossref","unstructured":"Douglas MAK, Ted S, Allen K, Kahl BS, Horwitz SM, Flinn IW et al. Treatment with the potent PI3K-\u03b4,\u03b3 inhibitor IPI-145 is associated with rapid decreases in specific cytokines, chemokines and matrix metalloproteinases in the serum of patients with chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma. ASH Annual Meeting 2013; Abstract # 1633.","DOI":"10.1182\/blood.V122.21.1633.1633"},{"key":"BFleu2015105_CR54","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.leukres.2009.09.032","volume":"34","author":"GM Hayes","year":"2010","unstructured":"Hayes GM, Busch R, Voogt J, Siah IM, Gee TA, Hellerstein MK et al. Isolation of malignant B cells from patients with chronic lymphocytic leukemia (CLL) for analysis of cell proliferation: validation of a simplified method suitable for multi-center clinical studies. Leuk Res 2010; 34: 809\u2013815.","journal-title":"Leuk Res"},{"key":"BFleu2015105_CR55","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1172\/JCI23409","volume":"115","author":"BT Messmer","year":"2005","unstructured":"Messmer BT, Messmer D, Allen SL, Kolitz JE, Kudalkar P, Cesar D et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest 2005; 115: 755\u2013764.","journal-title":"J Clin Invest"},{"key":"BFleu2015105_CR56","doi-asserted-by":"crossref","unstructured":"IPI-145 shows promise in CLL patients. Cancer Discov 2014; 4: 136.","DOI":"10.1158\/2159-8290.CD-NB2013-177"},{"key":"BFleu2015105_CR57","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1126\/science.287.5455.1040","volume":"287","author":"T Sasaki","year":"2000","unstructured":"Sasaki T, Irie-Sasaki J, Jones RG, Oliveira-dos-Santos AJ, Stanford WL, Bolon B et al. Function of PI3Kgamma in thymocyte development, T cell activation, and neutrophil migration. Science 2000; 287: 1040\u20131046.","journal-title":"Science"},{"key":"BFleu2015105_CR58","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.celrep.2013.07.011","volume":"4","author":"A Os","year":"2013","unstructured":"Os A, Burgler S, Ribes AP, Funderud A, Wang D, Thompson KM et al. Chronic lymphocytic leukemia cells are activated and proliferate in response to specific T helper cells. Cell Rep 2013; 4: 566\u2013577.","journal-title":"Cell Rep"},{"key":"BFleu2015105_CR59","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1182\/blood-2012-11-467670","volume":"122","author":"MF Pascutti","year":"2013","unstructured":"Pascutti MF, Jak M, Tromp JM, Derks IA, Remmerswaal EB, Thijssen R et al. IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells. Blood 2013; 122: 3010\u20133019.","journal-title":"Blood"},{"key":"BFleu2015105_CR60","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1146\/annurev.cellbio.17.1.615","volume":"17","author":"R Katso","year":"2001","unstructured":"Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, Waterfield MD . Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol 2001; 17: 615\u2013675.","journal-title":"Annu Rev Cell Dev Biol"},{"key":"BFleu2015105_CR61","first-page":"1667","volume":"63","author":"C Sawyer","year":"2003","unstructured":"Sawyer C, Sturge J, Bennett DC, O'Hare MJ, Allen WE, Bain J et al. Regulation of breast cancer cell chemotaxis by the phosphoinositide 3-kinase p110delta. Cancer Res 2003; 63: 1667\u20131675.","journal-title":"Cancer Res"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2015105.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2015105","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2015105.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T16:25:42Z","timestamp":1648743942000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2015105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,28]]},"references-count":61,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["BFleu2015105"],"URL":"https:\/\/doi.org\/10.1038\/leu.2015.105","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,28]]},"assertion":[{"value":"13 November 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"KB has a sponsored research agreement with Infinity Pharmaceuticals. MP, KF and JLK are employees of Infinity Pharmaceuticals. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}